EnsiliTech® Showcases Groundbreaking Biopharmaceutical Technology During Visit by HRH The Duke of Edinburgh at the University of Bath
Bristol, UK – 14th January 2025. Ensilitech, an innovative start-up developing pioneering solutions in the biopharmaceutical field, was honoured to be one of the key groups showcased during a visit by HRH The Duke of Edinburgh to the University of Bath on 14th January 2025. The Duke’s visit highlighted the university’s strong commitment to fostering cutting-edge research and supporting entrepreneurial ventures that aim to solve global challenges.
Ensilitech's revolutionary Ensilication® technology, which uses silica – the same material that sand is made from – to create a protective shell around vaccines, antibodies, and other biopharmaceuticals, was demonstrated to HRH The Duke of Edinburgh during the visit. This breakthrough technology can prevent the degradation of sensitive biopharmaceuticals when stored outside of cold storage environments, such as refrigerators or freezers, significantly improving the global distribution and accessibility of life-saving medicines.
The potential impact of Ensilitech’s technology extends beyond the lab, offering promising solutions for addressing the global health disparities related to storage and transportation of biopharmaceuticals. The technology’s ability to protect critical medicines in non-refrigerated conditions could revolutionize how vaccines and treatments are distributed, particularly in low and middle-income countries where access to reliable cold storage infrastructure is often limited.
“We are incredibly proud to have the opportunity to showcase our technology to HRH The Duke of Edinburgh today,” said Asel Sartbaeva, CEO of Ensilitech. “Our goal is to ensure that essential vaccines and other biopharmaceuticals can be safely transported and distributed to the people who need them most, no matter where they are in the world. The potential to improve access to healthcare, especially in regions with limited infrastructure, is incredibly exciting.”
Ensilitech’s participation in this prestigious event underscores its role at the forefront of scientific innovation and its commitment to improving healthcare on a global scale. As the company continues to develop and scale its technology, it remains focused on transforming the distribution and storage of vital medicines for global health equity.